Bayer's Monsanto sued COVID-19 vaccine makers Pfizer , BioNTech and Moderna in Delaware federal court on Tuesday for allegedly misusing its messenger RNA technology in manufacturing their vaccines, a ... ...

PresentationGood morning, and welcome to the Arrowhead Pharmaceuticals' Virtual KOL event. [Operator Instructions]. As a reminder, this call is being recorded, and a replay will be available on the Arrowhead website following the event.Vincent AnzaloneHead of Investor Relations & VP Thanks so much, Wilson, and thanks, everybody, for joining us today. We are excited to talk about our first interim results from our 2 obesity candidates, ARO-INHBE and ARO-ALK7. The press release went out this morning. So I'd l ...

Robinhood’s top lawyer is joining FINRA’s Board of Governors with three other appointments, including a former chairman of the Commodity Futures Trading Commission.In addition to being Robinhood Markets’ chief legal, compliance and corporate affairs officer, Dan Gallagher is a former commissioner of the Securities and Exchange Commission. Additionally, Gallagher was rumored to be a finalist to run the agency during Trump’s second term, before withdrawing his name from consideration in late 2024. Gallagher’s ...

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...

Market Performance - European stocks closed higher, with the pan European Stoxx 600 climbing 0.58% and the U.K.'s FTSE 100 increasing by 1.18% [1] - Several European markets, including Austria, Belgium, and Spain, also recorded gains, while Iceland, Ireland, Poland, and Russia ended weak [2] Company Highlights - Next Plc shares surged 5% after upgrading profit guidance, forecasting after-tax earnings of 738.8 pence per share, driven by a more than 10% surge in sales in December [3] - In the UK market, Fresnillo climbed about 5%, while AstraZeneca, Burberry Group, and several others gained between 3% to 5% [2] - JD Sports Fashion drifted down 4.4%, and Adidas ended lower by about 4.2% following a rating downgrade by Bank of America [4] Sector Performance - In the German market, Daimler Truck Holding gained 5.3%, and Infineon moved up 5% [4] - In France, EssilorLuxottica gained more than 5%, while Edenred and Kering ended higher by about 4.3% and 4%, respectively [5] - Polish parcel locker company shares soared more than 28% after announcing an indicative buyout offer [6] Economic Indicators - The HCOB Composite PMI in Germany decreased to 51.3 in December from 52.4 in November [6] - France's inflation eased to a seven-month low in December, with the consumer price index logging an annual increase of 0.8% [7] - EU harmonized inflation slowed unexpectedly in December to 0.7% from 0.8% in November [8]

Positive Phase 3 HERIZON-GEA-01 results support Ziihera as the HER2-targeted agent-of-choice in HER2+ first-line metastatic GEA and Ziihera plus chemotherapy to replace trastuzumab as the new standard of care, with or without tislelizumab regardless of PD-L1 status Late-breaking results to be presented at the 2026 ASCO Gastrointestinal Cancers Symposium (ASCO GI) on January 8, 2026 For U.S. media and investors only ® ® DUBLIN, Jan. 6, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announ ...

SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced full results from the Phase 3 HERIZON-GEA-01 trial evaluating ZIIHERA® (zanidatamab), a HER2-targeted bispecific antibody, in combination with chemotherapy, with and without PD-1 inhibitor TEVIMBRA® (tislelizumab), as a first-line treatment for HER2-positive (HER2+) locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). These data, inclu ...

Health care ETFs could emerge as one of the stronger performers in 2026 as investors grow cautious about pricey AI stocks. • State Street Health Care Select Sector SPDR ETF shares are trending higher. Why is XLV stock advancing?Analysts, cited by Reuters, see support coming from rising demand for weight-loss drugs, policy tailwinds and the sector's defensive qualities. Funds such as State Street Health Care Select Sector SPDR ETF (NYSE:XLV) and Vanguard Health Care Index Fund ETF (NYSE:VHT) offer exposure t ...

Core Viewpoint - Viatris (VTRS) has received an upgrade to a Zacks Rank 2 (Buy), indicating a positive trend in earnings estimates which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Movement - The Zacks rating system is based on the consensus measure of EPS estimates from sell-side analysts, reflecting the company's changing earnings picture [1][2]. - A strong correlation exists between earnings estimate revisions and near-term stock price movements, with institutional investors using these estimates to determine fair value [4][6]. Company Performance and Investor Sentiment - The upgrade in Viatris' rating signifies an improvement in the company's underlying business, which is expected to positively influence its stock price [5][10]. - Over the past three months, the Zacks Consensus Estimate for Viatris has increased by 2.2%, with expected earnings of $2.32 per share for the fiscal year ending December 2025, unchanged from the previous year [8]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a proven track record of Zacks Rank 1 stocks generating an average annual return of +25% since 1988 [7]. - Viatris' upgrade to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, indicating a strong potential for market-beating returns in the near term [9][10].

Key Takeaways J&J's diversified pharma and MedTech model supports steadier growth across cycles.JNJ's 2025 gains were driven by Innovative Medicine growth and improving MedTech performance.AZN's oncology-led growth is offset by patent expirations, Part D pressure and China-related headwinds.Johnson & Johnson (JNJ) and AstraZeneca (AZN) rank among the world’s largest pharmaceutical companies, each with a broad and diversified healthcare portfolio. Both companies have a strong presence in oncology. Other than ...